All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs
In a blockbuster endorsement of its gene-editing technology, Gilead $GILD has tapped Sangamo’s zinc finger nuclease approach to tailoring its next-gen programs for off-the-shelf as well as personalized therapies. And Gilead, which seized a leading spot in the CAR-T world with its acquisition of Kite, is fronting the deal with $150 million in cash and slightly more than $3 billion in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.